A massive soap recall is underway after DermaRite Industries, LLC, expanded its voluntary recall of over 30 personal care products due to potential contamination with Burkholderia cepacia complex (Bcc). The initial recall, issued in July 2025, was significantly broadened on August 27, 2025, encompassing a wider array of items as a precautionary measure. Consumers are urged to check their products immediately.
Scope of the Product Recall
The recall affects a diverse range of personal care products manufactured by DermaRite Industries. These include, but are not limited to, hand and body washes, lotions, hand sanitizers, and deodorants. According to the FDA, specific products implicated in the recall include Renew Skin Repair, KleenFoam antimicrobial foam soap, Gel Rite instant gel hand sanitizer, DermaKleen antiseptic lotion soap, DermaSarra external analgesic, and PeriGiene antiseptic cleanser. The products were distributed nationwide across the United States and in Puerto Rico.
The Burkholderia Cepacia Complex Threat
The primary concern driving this recall is the presence of Burkholderia cepacia complex (Bcc). This group of bacteria, commonly found in natural environments like soil and water, poses a limited threat to healthy individuals. However, as reported by Health, Bcc can lead to serious infections in those with weakened immune systems, chronic lung conditions such as cystic fibrosis, or even minor skin abrasions.
Health Risks and Vulnerable Populations
For individuals with compromised immune systems, Bcc infections can be particularly dangerous. As noted by Newsweek, the bacteria can enter the bloodstream, potentially causing sepsis, a life-threatening condition. Furthermore, many strains of Bcc exhibit antibiotic resistance, complicating treatment efforts. The Centers for Disease Control and Prevention (CDC) highlights that individuals with cystic fibrosis are particularly vulnerable to severe Bcc infections.
Company Response and Consumer Guidance
DermaRite Industries has taken steps to address the contamination issue. The company has communicated with its distributors and customers via email, advising them to immediately inspect their inventory and cease using any recalled products. Consumers are instructed to dispose of the affected items in accordance with local regulations.
Immediate Actions for Consumers
Consumers who possess any of the recalled products should take the following steps:
- Discontinue Use: Immediately stop using the product to avoid potential exposure to Bcc.
- Check Lot Numbers: Verify if the product’s lot number is included in the recall.
- Proper Disposal: Dispose of the product according to local guidelines for hazardous waste.
- Monitor for Symptoms: Be vigilant for any signs of infection, such as fever or fatigue.
- Seek Medical Advice: If you experience any symptoms after using the product, consult your physician or healthcare provider promptly.
No Reported Adverse Events Yet
As of the recall expansion announcement on August 27, 2025, DermaRite Industries stated that it had not received any reports of adverse events related to the recalled products. However, the company emphasizes the importance of consumer vigilance and encourages individuals to seek medical attention if they experience any concerning symptoms after using the products. The FDA is also monitoring the situation and encourages consumers and healthcare professionals to report any adverse events associated with the recalled products through the MedWatch program.
“Out of an Abundance of Caution”
The expansion of the recall underscores DermaRite’s commitment to consumer safety. The company, as noted by Fox Business, is acting “out of an abundance of caution” to mitigate any potential risks associated with the Bcc contamination. This proactive approach reflects a dedication to maintaining the highest standards of product quality and safety.
Conclusion
The DermaRite Industries’ soap recall highlights the importance of stringent quality control measures in the manufacturing of personal care products. While no adverse events have been reported to date, the potential health risks associated with Burkholderia cepacia complex warrant immediate action from consumers and distributors. By following the company’s guidance and remaining vigilant for any signs of infection, consumers can protect themselves from potential harm. The FDA continues to monitor the situation, emphasizing the importance of reporting any adverse events related to the recalled products.
